deferoxamine has been researched along with Cancer of Pancreas in 10 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Deferoxamine (DFO) is an efficient iron chelator, but its short circulation half-life and ability to induce hypoxia-inducible factor 1α (HIF1α) overexpression restricts its use as an antitumor agent." | 1.51 | Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1α Inhibitor Impairs Pancreatic Tumor Growth. ( Anderson, GJ; Cheng, K; Geranpayehvaghei, M; Han, X; Hao, J; Lang, J; Li, Y; Nie, G; Qin, H; Ren, H; Shi, J; Wang, X; Zhao, R; Zhao, X; Zhao, Y; Zheng, X, 2019) |
| "Pancreatic cancer is one of the most lethal types of cancer with a mortality rate of almost 95%." | 1.48 | Piperlongumine rapidly induces the death of human pancreatic cancer cells mainly through the induction of ferroptosis. ( Kasukabe, T; Kumakura, S; Yamaguchi, Y, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamaguchi, Y | 1 |
| Kasukabe, T | 1 |
| Kumakura, S | 1 |
| Lang, J | 1 |
| Zhao, X | 1 |
| Wang, X | 1 |
| Zhao, Y | 1 |
| Li, Y | 2 |
| Zhao, R | 1 |
| Cheng, K | 1 |
| Han, X | 1 |
| Zheng, X | 1 |
| Qin, H | 1 |
| Geranpayehvaghei, M | 1 |
| Shi, J | 1 |
| Anderson, GJ | 1 |
| Hao, J | 1 |
| Ren, H | 1 |
| Nie, G | 1 |
| Bauman, A | 1 |
| Valverde, IE | 1 |
| Fischer, CA | 1 |
| Vomstein, S | 1 |
| Mindt, TL | 1 |
| Houghton, JL | 2 |
| Zeglis, BM | 2 |
| Abdel-Atti, D | 2 |
| Sawada, R | 2 |
| Scholz, WW | 2 |
| Lewis, JS | 2 |
| Aggeler, R | 1 |
| Agnew, BJ | 1 |
| Nuhn, P | 1 |
| Künzli, BM | 1 |
| Hennig, R | 1 |
| Mitkus, T | 1 |
| Ramanauskas, T | 1 |
| Nobiling, R | 1 |
| Meuer, SC | 1 |
| Friess, H | 1 |
| Berberat, PO | 1 |
| Langlois, A | 1 |
| Bietiger, W | 1 |
| Sencier, MC | 1 |
| Maillard, E | 1 |
| Pinget, M | 1 |
| Kessler, L | 1 |
| Sigrist, S | 1 |
| Stolz, B | 3 |
| Smith-Jones, PM | 2 |
| Albert, R | 3 |
| Reist, H | 2 |
| Mäcke, H | 1 |
| Bruns, C | 3 |
| Reist, HW | 1 |
| Fridrich, R | 1 |
| Mäcke, HR | 2 |
| Smith-Jones, P | 1 |
| Maina, T | 1 |
10 other studies available for deferoxamine and Cancer of Pancreas
| Article | Year |
|---|---|
Piperlongumine rapidly induces the death of human pancreatic cancer cells mainly through the induction of ferroptosis.
Topics: Acetylcysteine; Amino Acid Chloromethyl Ketones; Animals; Antineoplastic Combined Chemotherapy Proto | 2018 |
Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1α Inhibitor Impairs Pancreatic Tumor Growth.
Topics: Administration, Oral; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Deferoxamine; Dru | 2019 |
Development of 68Ga- and 89Zr-Labeled Exendin-4 as Potential Radiotracers for the Imaging of Insulinomas by PET.
Topics: Animals; Deferoxamine; Exenatide; Gallium Radioisotopes; Insulinoma; Isotope Labeling; Mice; Mice, N | 2015 |
Pretargeted Immuno-PET of Pancreatic Cancer: Overcoming Circulating Antigen and Internalized Antibody to Reduce Radiation Doses.
Topics: Animals; Antibodies, Neoplasm; Antigens, Neoplasm; Cell Line, Tumor; Copper Radioisotopes; Deferoxam | 2016 |
Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; CA-19-9 Antigen; Cell Line, Tumor; Deferoxamine; Disease Models, An | 2015 |
Heme oxygenase-1 and its metabolites affect pancreatic tumor growth in vivo.
Topics: Analysis of Variance; Animals; Biliverdine; Carbon Monoxide; Cell Line, Tumor; Cell Proliferation; C | 2009 |
Adenoviral infection or deferoxamine? Two approaches to overexpress VEGF in beta-cell lines.
Topics: Adenoviridae; Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Deferoxamine; Gene Expression Reg | 2009 |
Biological characterisation of [67Ga] or [68Ga] labelled DFO-octreotide (SDZ 216-927) for PET studies of somatostatin receptor positive tumors.
Topics: Animals; Carrier Proteins; Deferoxamine; Gallium Radioisotopes; In Vitro Techniques; Octreotide; Pan | 1994 |
Gallium-67/gallium-68-[DFO]-octreotide--a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies.
Topics: Animals; Carcinoma, Islet Cell; Deferoxamine; Humans; In Vitro Techniques; Isotope Labeling; Octreot | 1994 |
New octreotide derivatives for in vivo targeting of somatostatin receptor-positive tumors for single photon emission computed tomography (SPECT) and positron emission tomography (PET).
Topics: Adenoma, Islet Cell; Animals; Binding, Competitive; Cell Membrane; Cerebral Cortex; Deferoxamine; Ga | 1993 |